This year’s JP Morgan struck a different tone than previous years—a very pleasant one, despite higher security anxieties ...

WuXi AppTec is parting ways with its U.S. medical device testing business, selling its two stateside locations to the ...

One of the biggest stories of last year was Lykos Therapeutics’ failure to get its MDMA candidate over the finish line for ...

After six years at Apellis, Chief Operating Officer Adam Townsend is saying goodbye to take on his first CEO job. The veteran ...

Notch Therapeutics is making “significant” layoffs to conserve its cash while the cell therapy biotech seeks out new partners ...

Boehringer Ingelheim’s investigational schizophrenia candidate has failed to improve cognitive impairment or functioning in a ...

Servier isn’t the first drug developer to spot a silver lining in Google Cloud. Ginkgo inked its own five-year partnership in ...

Avacta is stepping up development of its peptide-drug conjugate (PDC), kicking off expansion cohorts in multiple tumor types ...

Take a look back at the biggest stories of the week with Fierce Biotech’s conference's kickoff coverage here | Welcome to day ...

Serina Therapeutics is shedding a subsidiary to start the new year off debt-free. | Serina Therapeutics is shedding a ...

GE HealthCare is launching a new imaging research collaboration with the University of California, San Francisco, aimed at ...

The therapy, dubbed OST-HER2, uses a HER2-bioengineered form of the bacteria Listeria monocytogenes to trigger an immune ...